Karnataka’s Crackdown on Spurious Drugs: IP, Patents and Public Health

The Karnataka Food Safety and Drugs Administration (FSDA) has cancelled licences of 16 pharmaceutical retailers and wholesalers and suspended eight others, including the depot of multinational Pfizer in Nelamangala. The action follows a raid on a farmhouse in Bidadi that uncovered a ₹5.05 crore cache of repackaged, counterfeit medicines and the formation of a Special Investigation Team (SIT) to probe a wider network.

The Unlicensed Repurposing Racket

Investigators seized low‑cost medicines sourced from neighbouring states, injection‑filling machinery, forged labels and stamps. The seized stock was relabelled as high‑priced, life‑saving drugs of multinational origin.

• ▸16 licences cancelled, 8 suspended across Bengaluru, Hubballi and other districts.
• ▸₹5.05 crore worth of drugs, machinery and printing material seized on 18 August.
• ▸The SIT, headed by IPS officer C. Vamsi Krishna, is examining the supply chain and the role of the Pfizer depot.

The FSDA has blocked the batch numbers on its portal and sent samples for laboratory verification, signalling a rare, coordinated state response to a public‑health threat.

Legal Framework Governing Drug Licensing and IP

Drug licences in India are issued under the Drugs and Cosmetics Act, 1940, and enforced by state FSDA bodies. Parallelly, the protection of drug inventions rests on the Patents Act 1970, which incorporates the obligations of the TRIPS agreement.

• ▸Article 27 of TRIPS requires patentability for inventions across all technology fields, subject to novelty and industrial applicability.
• ▸Article 31 of TRIPS permits compulsory licensing in emergencies; India codified this in 2005 through Section 84 of the Patents Act.
• ▸The Competition Act 2002 empowers the Competition Commission of India to curb anti‑competitive practices in the pharmaceutical sector.

Together, these statutes aim to balance incentivising innovation with safeguarding public health, a balance now tested by the Karnataka case.

How TRIPS and Compulsory Licensing Intersect

When a drug is unavailable or unaffordable, the government may invoke compulsory licensing under Section 84, allowing a generic manufacturer to produce the patented product without the patent holder’s consent. The Karnataka episode does not involve a patent breach per se, but the relabelling of generic stock as patented medicines raises questions about the misuse of Intellectual property rights to deceive consumers.

• ▸Compulsory licences can be issued “in the public interest” or “in case of national emergency” per Article 31.
• ▸The 2005 amendment introduced a three‑step test: (i) reasonable requirements of the public, (ii) non‑availability of the patented drug at affordable prices, (iii) non‑infringement of the patent holder’s legitimate commercial interests.
• ▸The FSDA’s action, while primarily a regulatory enforcement, underscores the need for robust IP monitoring to prevent counterfeit exploitation of patented brand names.

Implications for Multinationals and Domestic Supply Chains

Pfizer’s decision to halt sales in Karnataka after refusing to cooperate with the SIT illustrates the tension between multinational firms and state regulators. While multinational companies rely on strong patent protection to recoup R&D costs, the prevalence of counterfeit repackaging erodes brand trust and can trigger market exits.

• ▸The FSDA’s suspension affects the supply of genuine Pfizer products in the state, pushing patients toward government hospitals where “everything is original,” as Health Minister U.T. Khader asserted.
• ▸Domestic wholesalers face heightened scrutiny, potentially increasing compliance costs and slowing distribution of legitimate generics.
• ▸The episode may prompt other states to adopt similar licence‑cancellation powers, reshaping the pharmaceutical landscape across India.

Way Forward: Strengthening Enforcement and Innovation

To curb counterfeit networks, India must integrate IP surveillance with drug‑safety inspections, leveraging digital traceability such as QR‑code verification mandated by the FSDA. Simultaneously, fostering a vibrant generic industry under the Patents Act’s flexibilities can ensure affordable access without compromising innovation.

• ▸Expand the use of the “batch‑blocking” portal to all states for real‑time alerts.
• ▸Encourage public‑private partnerships to develop low‑cost, high‑quality generics under Section 84 when patents are underutilised.
• ▸Align the Competition Commission’s oversight with FSDA actions to deter anti‑competitive hoarding of genuine medicines.

A coordinated approach can protect public health, uphold Intellectual property rights and sustain India’s ambition to become a global hub for affordable, high‑quality pharmaceuticals.